Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen.
Adult
Area Under Curve
Bayes Theorem
Blood Specimen Collection
/ methods
Busulfan
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Deoxycytidine
/ administration & dosage
Drug Administration Schedule
Drug Dosage Calculations
Drug Monitoring
/ methods
Etoposide
/ administration & dosage
Female
Hematologic Neoplasms
/ blood
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Male
Middle Aged
Transplantation Conditioning
/ methods
Vidarabine
/ administration & dosage
Gemcitabine
HCT
busulfan
pharmacokinetics
test dose
transplantation
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
01
08
2018
accepted:
12
11
2018
pubmed:
5
12
2018
medline:
14
8
2020
entrez:
5
12
2018
Statut:
ppublish
Résumé
This study aimed to predict the area under the curve (AUC) of the initial busulfan dose using a test dose with the sparse sampling scheme in adult patients who underwent hematopoietic cell transplant. A test dose of 0.8 mg/kg busulfan was used 2 days before twice-daily intravenous busulfan-based conditioning regimens were administered. The AUC and the clearance (CL) were calculated for both the test dose and the first dose (AUC
Substances chimiques
Deoxycytidine
0W860991D6
Etoposide
6PLQ3CP4P3
Cyclophosphamide
8N3DW7272P
Vidarabine
FA2DM6879K
Busulfan
G1LN9045DK
fludarabine
P2K93U8740
Gemcitabine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
638-645Informations de copyright
© 2018, The American College of Clinical Pharmacology.